CHMP Approvals Signal Shift, JCA Device Rollout Begins

Episode 19 — 02 June 2026 CHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 trends report. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

0:00

Welcome to Access Brief, the daily AI podcast on Qior, HTA, and market access. I'm Marcus with Sarah. Today, CHMP's May approvals indicating development shifts, medical device JCAs launching, and AI topping ISPOR trends. Let's get into it. CHMP recommended eight medicines at its May meeting, but it's the 13 indication extensions that tell the real story. 21 clinical development programs survived full scientific scrutiny in a single session. The approvals themselves are standard. Neurandomelast for IPF, chemizistrint for breast cancer, lira glutide for weight management. But 13 extensions suggest sponsors are getting smarter about life cycle management from initial approval. Or it reflects regulatory pathway optimization. Extensions require less de novo evidence generation than new molecular entities. We're seeing portfolio strategies shift toward indication expansion rather than novel assets. That's commercially driven thinking. The evidence bar for extensions isn't lower, it's different. These programs still needed robust clinical packages. The real signal is that sponsors are building evidence strategies around platform molecules rather than betting everything on single indications. Which makes perfect sense when you're facing JCA scrutiny. Better to establish your evidence base once and expand systematically than risk multiple novel assessments. But it also means we're moving toward a more concentrated pharmaceutical landscape. The oral semaglutide approval changes everything for GLP1 market access. First oral formulation for weight management, that's not incremental innovation. It's huge for adherence and patient preference, but the real question is whether NICE and other HTA bodies will differentiate on administration route. Injectable semaglutide already has established cost-effectiveness thresholds. Patient preference has value, but quantifying it for HTA bodies remains problematic. Two to five JSCs for devices versus eight to twelve for medicines. Medical device evidence frameworks aren't as mature as pharmaceutical assessments. Starting small allows them to identify procedural issues before scaling to the anticipated 50 JCAs for medicinal products. But five assessments won't generate meaningful precedent for device manufacturers. They need volume to establish consistent interpretation of evidence requirements across member states. Consistency matters less than getting the framework right. Rushing device JCAs without proper methodology development would create more problems than it solves. The pharmaceutical JCAs have already shown capacity constraints. True, but device manufacturers need clarity on evidence expectations. Staying in pilot mode indefinitely serves no one's interests. AI topped ISPORS Trends Report Rising from number three. That's rapid acceleration in a field that typically moves incrementally. It reflects real adoption across systematic literature reviews and predictive analyses. But I'm skeptical about AI's actual impact on evidence generation quality. Speed isn't everything in HEOR. The systematic review acceleration is genuine value. Manual literature, searches, and data extraction are massive resource drains. AI can democratize high-quality evidence synthesis for smaller organizations. Democratization sounds positive until you consider that HTA bodies will raise evidence standards accordingly. If AI makes comprehensive reviews easier, they'll expect more comprehensive submissions. We're in an evidence arms race. But better evidence benefits everyone. If AI enables more thorough analysis of real-world data for post-market surveillance and outcomes research, that strengthens the entire evidence base. The ISPR discussions in Philadelphia focused heavily on AI integration with real-world evidence and patient-centered assessment. That suggests the field recognizes the validation challenges. Recognition and resolution are different things. We're still in the experimental phase. CHMP's output suggests European drug development is becoming more strategic and evidence focused. While device JCAs and AI adoption show the field is evolving rapidly, sometimes faster than our methodologies can keep pace. Back tomorrow on AccessBrief. Show notes at outcomes analytica.numboss